The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25119106.
- Also identified by DOI 10.1371/journal.pone.0104906 and PMC identifier 4131979.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PML/RARA is the oncoprotein driving acute promyelocytic leukemia (APL). It suppresses genes expression by recruitment of a number of transcriptional repressors, resulting in differentiation block and malignant transformation of hematopoietic cells. Here, we found that mice primary hematopoietic progenitor cells (HPCs), transduced by DNA-binding-defective PML/RARA mutants, were deficient in colony formation. Further experiments showed that DNA-binding-defective PML/RARA mutants could not repress the transcription of retinoic acid regulated genes. Intriguingly, there were no significant differences of the micro-speckled intracellular distribution between the mutants and wild-type PML/RARA. Some retinoic acid target genes regulated by PML/RARA are involved in not only differentiation block but also hematopoietic cell self-renewal. Altogether, our data demonstrate that direct DNA-binding is essential for PML/RARA to immortalize hematopoietic cells, while disruption of PML-nuclear body does not seem to be a prerequisite for hematopoietic cell transformation.
Medical subject headings
- Cell Transformation, Neoplastic
- Hematopoietic Stem Cells
- Leukemia, Promyelocytic, Acute
- Nuclear Proteins
- Oncogene Proteins, Fusion
- Receptors, Retinoic Acid
- Transcription Factors
- Tumor Suppressor Proteins